Objectives
==========

Carbapenems such as imipenem (IM) provide important antimicrobial activities against *Pseudomonas aeruginosa* (*PA*) and *Acinetobacter calcoaceticus/baumanii* (*ACB*). Additionally co-administration with an aminoglycoside provides broad-spectrum coverage. The current activity of IM, and the activity of IM and gentamicin (GN) or amikacin (AK), considered together, was reviewed by analysis of cross-susceptibility to this combination, as reported to physicians, by clinical microbiology laboratories in Germany.

Methods
=======

Data were analyzed (January 1999-October 2002) from The Surveillance Network^®^ (TSN) Database Germany, an electronic surveillance system that collects routine susceptibility test results from 169 hospital laboratories distributed throughout the country. Only data from nonrepeat isolates from patients \> 17 years of age, located on ICUs, and derived from antibiotics concomitantly tested were included in the analysis. NCCLS (2002) breakpoints were used to interpret the data.

Results
=======

For all *PA* (*n* = 1316) isolated from lower respiratory tract infection (LRTI) specimens during 1999--2000, 65.3% were reported susceptible (S) and 20.9% resistant (R) to IM. The following susceptibility and resistance frequencies were found for *PA* from LRTI, reported by year: 1999 (*n* = 127; 65.4% S; 31.5% R), 2000 (*n* = 346; 66.5% S; 28.9% R), 2001 (*n* = 539; 63.5% S; 15.4% R), and 2002 (*n* = 304; 67.1% S; 17.1% R). Among *PA* from blood reported by year: 1999 (*n* = 7; 85.7% S; 14.3% R), 2000 (*n* = 20; 80.0% S; 15.0% R), 2001 (*n* = 31; 74.2% S; 16.1% R), and 2002 (*n* = 39; 84.6% S; 12.8% R). Considering data of IM combined with an aminoglycoside, for *PA* from LRTI isolated during 2000--2002, 86.3% of isolates were S (*n* = 1634; 5.8% R) to both IM and gentamicin (GT), and 93.8% of isolates were S (*n* = 1171; 2.8% R) to IM and AK. *PA* isolates from blood were 89.1% S (*n* = 64; 3.1% R) to the combination of IM and GT, and 100% S (*n* = 45) to the combination of IM and AK. Overall (2000--2002) for *ACB* isolated from LRTI, 98.2% were S (*n* = 225; 0% R) compared with 100% S (*n* = 25) for blood isolates. For *ACB* by year, the following IM susceptibility percentages were detected: 90.5% S in 2000 (*n* = 21; 9.5% R), 99.3% S in 2001 (*n* = 143; 0.7% R), and 97.5% S in 2002 (*n* = 163; 0% R).

Conclusions
===========

In Germany, IM susceptibility has remained consistent for *PA* since 1999 and *ACB* since 2000, and no increase in resistant phenotypes was detected. Combinations of IM with an aminoglycoside still approach 100% coverage against *PA*.
